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INTRODUCTION
Benign prostatic hyperplasia (BPH), which is common in older men, is an enlargement of the prostate gland that may lead to bladder outlet obstruction, lower urinary tract symptoms, and reduced quality of life [1] . Normal bladder filling and storage processes require accommodation for increasing urine volume under low intravesical pressure with appropriate sensation. The sphincter remains closed as intra-abdominal pressure increases and involuntary bladder contractions do not occur [2] . However, patients with BPH show voiding and storage symptoms due to bladder outlet obstruction following enlargement of the prostate [3, 4] .
Bladder outlet obstruction caused by BPH is associated with marked alterations in bladder structure and function, including detrusor overactivity, with symptoms of urinary frequency, urgency, and urge incontinence [5] . More than half of patients with BPH/lower urinary tract symptoms have overactive bladder symptoms. The management of BPH includes nonpharmacological, pharmacological, and surgical interventions, and the choice of therapy depends on the pattern and severity of symptoms. Although surgery is the definitive treatment for BPH, the risks, complications, and costs of surgical intervention suggest the need for effective and safe noninvasive treatments, such as drug therapy. The pharmacological management of lower urinary tract symptoms by BPH includes several categories of drugs with different modes of action.
α1-Adrenoceptor (α1-AR) blockers have been widely used to treat BPH, as they decrease muscle tone and inhibit smooth muscle contraction by blocking adrenergic receptors, which are abundant in the bladder neck, prostatic capsule, and prostatic tissue [6] . Thus, α1-AR blockers are first-line treatments and have been shown to be effective and safe [7, 8] . Recently, to increase their therapeutic effects, α1-AR blockers have been used to control BPH in the form of combination therapy, as well as monotherapy. Combination therapy is particularly promising for improving BPH-induced lower urinary tract symptoms.
Therefore, we compared the effect of combination therapy with α1-AR blockers (tamsulosin with naftopidil) to the effect of tamsulosin monotherapy or naftopidil monotherapy using BPH rats. In this study, cystometry was performed, as well as immunohistochemistry for c-Fos and nerve growth factor (NGF) and histochemistry for nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH-d) in the neuronal voiding centers (medial preoptic area [MPA] , ventrolateral periaqueductal gray [vlPAG] , pontine micturition center [PMC] , and spinal cord L4-L5).
MATERIALS AND METHODS

Animals and Treatments
Adult male Sprague-Dawley rats, weighing 210 ± 5 g (9 weeks old), were used for the experiments. All animal procedures complied with the regulations of the Institutional Care and Use Committee (KHUASP[SE]-14-047) of Kyung Hee University and were performed in accordance with the guiding principles for the care and use of animals approved by the Council of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The rats were housed under controlled temperature (23°C ± 2°C) and lighting (8 AM to 9 PM) conditions with food and water available ad libitum. The animals were randomly divided into the following 5 groups (n =10 in each group): the sham operation group, the BPH-induced group, the BPH-induced and tamsulosin-treated group, the BPH-induced and naftopidil-treated group, and the BPH-induced and combination-treated group.
The recommended daily allowance of each drug was administered as follows: 0.2 mg/kg of tamsulosin (Harnal, Astellas Pharma, Inc., Tokyo, Japan), 75 mg/kg of naftopidil (Flivas, Asahi Kasei Pharma, Tokyo, Japan), and 0.2 mg/kg of tamsulosin+75 mg/kg of naftopidil in the combination therapy group. Rats in the drug-treated groups orally received each drug once a day for 30 consecutive days after orchiectomy. The animals in the control and BPH-induced groups received the same amount of distilled water.
Induction of BPH
The BPH animal model was made following a previously described method [9] . The rats were anesthetized with Zoletil 50® (50 mg/kg; Virbac Laboratories, Carros, France). The testes and epididymis were exposed through a midline ventral scrotal incision, and the extratesticular rete testis together with the pampiniform plexus vessels were ligated. Then, the testes were removed, and the ligated efferent ductules and epididymis were returned to the scrotum. In the sham-operation rats, the testes were exposed, manipulated, and then reinserted into the scrotum. After surgery, the scrotal incision was closed by suturing. After orchiectomy, BPH was induced by a subcutaneous injection of testosterone (20 mg/kg; Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 30 days. 
Cystometry
Voiding contraction pressure and the interval contraction time were determined following a previously described method [10, 11] . Cystometry was performed 32 days after orchiectomy. The rats were anesthetized with Zoletil 50 (10 mg/kg, interperitoneally; Virbac Laboratories). A sterile polyethylene catheter (PE50) with a cuff was implanted in the bladder through an abdominal midline incision into the dome and held in place by a purse-string suture. The catheter was connected to a pressure transducer (Harvard Apparatus, Holliston, MA, USA) and syringe pump (Harvard Apparatus) via a 3-way stopcock to record the intravesical pressure and to infuse saline into the bladder. After the bladder was emptied, cystometry was performed by infusing 0.5 mL of saline. Voiding contraction pressure and interval contraction time in the bladder were monitored using Labscribe (iWork System Inc., Dover, NH, USA).
Tissue Preparation
The animals were sacrificed immediately after evaluating their voiding function by cystometry, following a previously described method [10, 12] . The rats were anesthetized using Zoletil 50 (10 mg/kg, interperitoneally; Virbac Laboratories), transcardially perfused with 50mM phosphate-buffered saline (PBS), and fixed with freshly prepared 4% paraformaldehyde in 100 mM phosphate buffer (pH, 7.4). The brain and spinal cord were dissected and stored overnight in the same fixative, and then transferred into 30% sucrose for cryoprotection. For immunohistochemistry, the slices were coronally sectioned at a thickness of 40 μm using a cryostat (Leica, Wetzlar, Germany). The PMC was selected from the region spanning from Bregma -9.68 to -9.80 mm, the vlPAG was selected from the region spanning from Bregma -7.64 to 8.00 mm, the MPA was selected from the region spanning from Bregma -0.26 to 0.80 mm, and the spinal cord was selected from the L4-5 regions. On average, 10 sections in each region were collected from each rat.
Immunohistochemistry for c-Fos and NGF
An immunohistochemical analysis was conducted to evaluate c-Fos and NGF expression in the MPA, vlPAG, PMC, and spinal cord L4-5 regions, following a previously described method [10, 12] . Free-floating tissue sections were incubated overnight with rabbit anti-c-Fos and mouse anti-NGF antibodies (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the sections were incubated for 1 hour with biotinylated anti-rabbit cFos and anti-mouse NGF secondary antibodies (1:200; Vector Laboratories, Burlingame, CA, USA). Next, the sections were incubated with avidin-biotin-peroxidase complex (Vector Laboratories) for 1 hour at room temperature. For staining, the sections were incubated in 0.03% DAB and 0.03% hydrogen peroxide for 5 minutes. The sections were mounted onto gelatincoated slides. The slides were air-dried overnight at room temperature, and coverslips were mounted using Permount (Fisher Scientific, Waltham, MA, USA).
Histochemistry for NADPH-d
To measure nitric oxide synthase (NOS) activity in the neuronal voiding centers, histochemistry for NADPH-d was performed following a previously described method [10] . Briefly, free-floating sections were incubated at 37°C for 60 minutes in 100mM PBS (pH, 7.4) containing 0.3% Triton X-100, 0.1-mg/ mL nitroblue tetrazolium, and 0.1-mg/mL β-NADPH. The sections were washed 3 times with PBS and mounted onto gelatincoated slides. The slides were air-dried overnight at room temperature, and coverslips were mounted using Permount (Fisher Scientific).
Data Analysis
The numbers of c-Fos-positive, NGF-positive, and NADPH-dpositive cells in the MPA, vlPAG, PMC, and spinal cord L4-L5 regions were counted hemilaterally through a light microscope (Olympus, Tokyo, Japan). The area of the MPA, PMC, vlPAG, and spinal cord L4-5 regions from each slice was measured using an Image-Pro Plus computer-assisted image analysis system (Media Cyberbetics Inc., Silver Spring, MD, USA) attached to a light microscope (Olympus).
Statistical analysis was performed using 1-way analysis of variance followed by the Duncan post hoc test, and the results are expressed as the mean ± standard error of the mean. Significance was set at P < 0.05.
RESULTS
Voiding Contraction Pressure and Interval Contraction Time
The voiding contraction pressure and interval contraction time from cystometry are presented in Fig. 1 . These results show that voiding contraction pressure and the interval contraction time were significantly decreased by the induction of BPH (P < 0.05). Monotherapy with tamsulosin or naftopidil did not exert a significant effect on voiding contraction pressure or the interval contraction time, whereas combination therapy (tamsulosin with naftopidil) significantly increased voiding contraction pressure and the interval contraction time in the BPH rats (P < 0.05).
c-Fos Expression in Neuronal Voiding Centers
Photomicrographs of c-Fos expression in the neuronal voiding centers are presented in Fig. 2 . The present results show that cFos expression in neuronal voiding centers was significantly increased by the induction of BPH (P < 0.05). Monotherapy with tamsulosin or naftopidil showed an inhibitory effect on c-Fos expression depending on the site in the neuronal voiding centers of BPH rats (P < 0.05). Combination therapy (tamsulosin with naftopidil) led to an even greater reduction in c-Fos expression at all sites of the neuronal voiding centers of BPH rats (P < 0.05).
NGF Expression in Neuronal Voiding Centers
Photomicrographs of NGF expression in the neuronal voiding centers are presented in Fig. 3 . The present results show that NGF expression in neuronal voiding centers was significantly increased by the induction of BPH (P < 0.05). Monotherapy with tamsulosin or naftopidil showed an inhibitory effect on NGF expression depending on the site in the neuronal voiding centers of BPH rats (P < 0.05). Combination therapy (tamsulosin with naftopidil) showed an even greater reduction in NGF expression at all sites of the neuronal voiding centers of BPH rats. 
NOS Expression in Neuronal Voiding Centers
Photomicrographs of NADPH-d expression in the neuronal voiding centers are presented in Fig. 4 . NOS expression in neuronal voiding centers was significantly increased by the induction of BPH (P < 0.05). Monotherapy with tamsulosin or naftopidil showed an inhibitory effect on NOS expression depend- ing on the site in the neuronal voiding centers of BPH rats (P < 0.05). Combination therapy (tamsulosin with naftopidil) showed an even greater reduction in NOS expression at all sites of the neuronal voiding centers of BPH rats. 
DISCUSSION
Exogenous testosterone supplementation has been repeatedly shown to induce prostate enlargement, and therapeutic drugs for BPH target prostate size [13] . Decreased voiding pressure and contraction time with enlargement of the prostate occurred following the administration of testosterone [13, 14] . In the present study, voiding contraction pressure and interval contraction time were decreased by testosterone injections, demonstrating that BPH was induced by repeated testosterone injections.
For the treatment of bladder outlet obstruction by BPH, α1-antagonists are the most widely used pharmacological agents [15] . Tamsulosin exhibits a dominant affinity to the α1A-AR subtype compared to the α1D-AR subtype, and tamsulosin exerts distinct actions on the prostate, external sphincter, and urethra [16] . Naftopidil has a 3 fold higher affinity for the α1D-ARsubtype than for the α1A-AR subtype, and naftopidil shows different effects on lower urinary tract symptoms because many α1D-ARs exist in the bladder neck [17] . Both α1-AR subtype antagonists alleviate bladder outlet obstruction symptoms, such as residual urine and urinary urge sensation, by reducing the prostate size [18] . Overactive bladder symptoms, including frequency, urgency, nocturia, and urgency incontinence, were decreased by α1-AR antagonists in clinical and animal studies [12, 19] . Furthermore, α1-AR antagonists increase bladder capacity and decrease frequency [10, 20] . Each α1-AR antagonist has unique properties based on its affinity profile and different effects on the central nervous system [17, 21] . In the present study, combination therapy of tamsulosin with naftopidil enhanced voiding contraction pressure and interval contraction time. In contrast, monotherapy with tamsulosin or naftopidil did not exert a significant effect on voiding contraction pressure or the interval contraction time in BPH rats. These effects might be ascribed to the agonistic effects of tamsulosin and naftopidil in areas of the lower urinary tract such as the urethra, bladder, and prostate.
Voiding function is controlled by central micturition centers. The PMC plays an important role in controlling urinary bladder or urethral functions. During micturition, sympathetic motor neurons are suppressed and parasympathetic motor neurons are activated. PMC neurons directly activate parasympathetic preganglionic motor neurons, causing bladder contraction and sustained relaxation of the urethral sphincter [22] . vl-PAG is important for controlling micturition through both afferent and efferent pathways. The efferent inhibitory signal passes through the PAG to the pons, and this excessive inhibitory signal triggers a reflex in the PMC, resulting in urethral sphincter relaxation [23] . The PAG-PMC projection is thought to be involved in the micturition reflex. The MPA sends projections to the PMC that synapse on neurons directly though projections to the spinal cord [24] . In this context, voiding is under the control of brain areas such as the prefrontal cortex, anterior circulate cortex, insula, hypothalamus, and spinal cord [23] .
Enhanced c-Fos expression represents neuronal activation [25] , and noxious stimulation of the muscle, joint, and viscera increased the number of c-Fos-positive neurons in the vlPAG [26] . Chemical irritation of the bladder also enhanced c-Fos expression in the PAG and MPA of rats [27] . Nitric oxide (NO) regulates vascular smooth muscle tone and neurotransmission in the peripheral and central nervous systems [28] . The NO pathway is implicated in pathological bladder activity [10, 29] . NO levels in the neuronal voiding centers also control lower urinary tract status [30] . NOS expression in neuronal voiding centers increased after cyclophosphamide injection, indicating that the induction of overactive bladder increased NO levels in the neuronal voiding centers [10] . In the present study, monotherapy with tamsulosin or naftopidil showed inhibitory effects on testosterone-induced c-Fos, NGF, and NOS expression depending on the site in the neuronal voiding centers. In particular, combination therapy of tamsulosin with naftopidil led to a greater reduction of c-Fos, NGF, and NOS expression at all sites in the neuronal voiding centers. These results suggest that cFos, NGF, and NOS in the neuronal voiding centers are involved in the modulation of micturition and that combination therapy more potently inhibits neuronal activation in the neuronal voiding centers of BPH rats.
In conclusion, combination therapy of tamsulosin and naftopidil may inhibit neuronal activity in the neuronal voiding centers to a greater extent than monotherapy with tamsulosin or naftopidil, and the enhanced inhibitory signal may relax the urethral and prostate smooth muscle. As combination therapy showed greater efficacy for the treatment of BPH than monotherapy, combination therapy can be considered as a novel therapeutic method for BPH.
